Welcome from the Executive Director

KAIMRC sets its eyes on becoming a regional leader in biomedical research.

READ

N/A

King Abdullah International Medical Research Center (KAIMRC) is witnessing the dawn of a new era with a strategy that focuses on selected diseases as priority areas for research and development (R&D). Our new roadmap will help optimise KAIMRC’s resources and ensure the best possible management of this thriving R&D centre, which is represented by multiple branches across the Kingdom of Saudi Arabia.

KAIMRC has succeeded in quickly positioning itself at the level of other major national biomedical research institutions. The centre aims to establish a strong foothold on the path toward success with the goal of reaching the global biomedical R&D stage within a few years. 

In an attempt to reach all our stakeholders and partners locally, regionally and internationally, this new magazine, Innovations, is dedicated to keeping readers abreast of R&D activities within KAIMRC, as well as highlighting significant biomedical R&D breakthroughs relevant to KAIMRC’s strategic areas.

We hope that Innovations will represent an attractive window for potential partners as well as those interested in joining KAIMRC to learn more about our activities and to share our enthusiasm for building a vibrant biomedical and clinical research centre in the Kingdom of Saudi Arabia.  

References

 

Read this next

Leaders chart the path for more clinical trials

Researchers, regulators, and experts from the medical industry gathered for the tenth year to share knowledge and exchange experiences on advancing the medical field through translational research

KAIMRC leads the kingdom into the first phase I clinical trial 

The forum celebrated the success of a three-year push that led to KAIMRC kicking off the first phase I clinical trial to be held in Saudi Arabia, testing a potential vaccine against MERS-CoV 

Researchers aim to grow translational research

Forum participants made suggestions about how Saudi Arabia can reach its ambitious 2030 targets to increase clinical trials from six trials per 1,000 doctors to 100 trials, and capture 1% of the global $1.5 billion annual pharmaceutical investments in clinical trials